Stonehaven Incubate has teamed up with Sports Performance Tracking (SPT) and veterinary pain specialist, Dr. B Duncan X Lascelles – all leaders in their respective fields – to create a new venture that will commercialise sensor technology to improve animal health. AniV8TM (pronounced An-i-vate) is a company designed to become the leading developer of clinical sensor technology recommended by veterinarians to diagnose and monitor common animal disease states.
AniV8TM has been formed to commercialise its first product, a novel approach to measuring the impact of osteoarthritis (OA) pain in companion animals. It will offer the first wearable for dogs and cats to diagnose and monitor OA-pain – agnostic to age, breed and lifestyle – using proprietary algorithms to measure the quality of movement.
Working with Agile Sciences, Stonehaven Incubate has launched Anifera to research and develop solutions for adjunct therapy with antibiotics in animal health, therefore improving their efficacy and ultimately reducing their use in animals.
Anifera will have the exclusive rights to manufacture, develop and commercialise a family of molecules in all applications in animal health.
Its proof-of-concept trials initially focused on reducing the impact of naturally occurring mastitis and proved to be safe and efficacious.
Touchlight Aquaculture LLCtouchlightaqua.com
Touchlight Genetics LLC and Stonehaven Incubate AG have formed a new joint venture company, Touchlight Aquaculture LLC, to combine expertise, intellectual property and platform technology.
Touchlight Aquaculture will utilize Touchlight Genetics’ innovative DNA-based Doggybonetm platform to develop new vaccine solutions, focused on providing solutions exclusively in the field of aquaculture. Touchlight’s technology provides a unique, synthetic DNA vector system in combination with an enzymatic process, allowing for larger scale commercial production, at a significantly lower cost.
In partnership with Regenosine, Stonehaven Incubate has established Vetosine, a new company that will develop and commercialize a first-in-class disease modifying osteoarthritis drug (DMOAD) for animals, with an initial focus on dogs.
The company’s aim is to increase therapy options for dogs with osteoarthritis beyond simple nonsteroidal anti-inflammatory drugs (NSAIDs), diet and exercise. Vetosine will provide a proven disease modifying drug that will strengthen clinical outcomes and improve the pet’s quality of life by maintaining healthy joint cartilage.